Anti-CD137-liposomes are innovative agents that enhance anti-tumor immune responses by delivering anti-CD137 antibodies directly to tumor sites. CD137 activation promotes T cell proliferation and survival, making it crucial for immune activation in cancer therapy. This localized delivery system improves therapeutic efficacy while minimizing systemic side effects compared to traditional systemic administration. Studies in murine B16F10 melanoma models show its potential for controlling both primary and distant tumors. Overall, anti-CD137-liposomes represent a promising strategy for cancer immunotherapy, leveraging the immune system with reduced risks.
Download resources about recombinant antibody development and antibody engineering to boost your research.
Select a product category from the dropdown menu below to view related products.
CAT | Product Name | Application | Type |
---|---|---|---|
TAB-179 | Anti-Human 4-1BB Recombinant Antibody (TAB-179) | ELISA, FC, IP, FuncS, IF, Neut, ICC | IgG4 - kappa |
TAB-457CQ | Anti-Human TNFRSF9 Recombinant Antibody (TAB-457CQ) | ELISA, IHC, FC, IP, IF, FuncS | IgG2, λ |
There are currently no Customer reviews or questions for VS-1024-FY200. Click the button above to contact us or submit your feedback about this product.
For Research Use Only. Not For Clinical Use.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.